Liang Ya-Nan, Zhang Zuwang, Song Ji, Yang Fuwei, Yang Pan
Department of Otolaryngology, University-Town Hospital of Chongqing Medical University, Chongqing 401331, China.
Department of Respiratory, University-Town Hospital of Chongqing Medical University, Chongqing 401331, China.
Evid Based Complement Alternat Med. 2022 Apr 15;2022:1116535. doi: 10.1155/2022/1116535. eCollection 2022.
Signal transduction and activator of transcription 3 (STAT3) is an oncogene with transcriptional activity. In recent years, there have been several studies concerning the clinicopathological significance of the expression of the STAT3 protein in thyroid cancer. However, the results are still inconsistent. In this study, we conducted a meta-analysis to evaluate the relationship between the expression of STAT3 protein and thyroid cancer susceptibility and its clinicopathological characteristics.
We searched the China National Knowledge Infrastructure (CNKI) database, Chinese Biomedical Literature Database (CBM), Chinese Scientific and Journal Database (VIP), Wanfang, PubMed, and EMBASE. The time frame of the publication search was from the establishment of each of the databases until December 2021. We performed a meta-analysis to quantitatively evaluate the relationship between the expression of the STAT3 protein in thyroid cancer and its clinicopathological characteristics.
A total of eight articles were included in the meta-analysis, covering 448 thyroid cancer patients and 227 controls. Results indicated that the expression of STAT3 protein in thyroid cancer tissue is highly expressed (OR = 14.41, 95% CI (6.94, 29.91), < 0.001). Besides, we also discovered that STAT3 protein is negatively correlated with thyroid cancer tumor diameter and TNM stage (OR = 0.13, 95% CI (0.05, 0.33), < 0.001; OR = 0.40, 95% CI (0.24, 0.67), < 0.001) and positively correlated with lymph node metastasis (OR = 2.83, 95% CI (1.08, 7.46), = 0.035). However, STAT3 expression is not related to gender (OR = 0.88, 95% CI (0.54, 1.44), = 0.609), age (OR = 0.54, 95% CI (0.21, 1.36), = 0.191), capsular invasion (OR = 2.98, 95% CI (0.23, 38.29), = 0.403), or tumor multiplicity (OR = 0.25, 95% CI (0.003, 19.28), = 0.533).
This study reveals that STAT3 protein expression is significantly related to the susceptibility and clinicopathological characteristics of thyroid cancer. It also suggests that STAT3 may be a potential predictor of the clinical progression of thyroid cancer.
信号转导与转录激活因子3（STAT3）是一种具有转录活性的癌基因。近年来，有多项关于STAT3蛋白表达在甲状腺癌中的临床病理意义的研究。然而，结果仍不一致。在本研究中，我们进行了一项荟萃分析，以评估STAT3蛋白表达与甲状腺癌易感性及其临床病理特征之间的关系。
我们检索了中国知网数据库（CNKI）、中国生物医学文献数据库（CBM）、维普中文科技期刊数据库（VIP）、万方数据库、PubMed和EMBASE。文献检索的时间范围是从每个数据库建立至2021年12月。我们进行了一项荟萃分析，以定量评估甲状腺癌中STAT3蛋白表达与其临床病理特征之间的关系。
荟萃分析共纳入8篇文章，涵盖448例甲状腺癌患者和227例对照。结果表明，甲状腺癌组织中STAT3蛋白表达呈高表达（OR = 14.41，95%CI（6.94，29.91），P < 0.001）。此外，我们还发现STAT3蛋白与甲状腺癌肿瘤直径和TNM分期呈负相关（OR = 0.13，95%CI（0.05，0.33），P < 0.001；OR = 0.40，95%CI（0.24，0.67），P < 0.001），与淋巴结转移呈正相关（OR = 2.83，95%CI（1.08，7.46），P = 0.035）。然而，STAT3表达与性别（OR = 0.88，95%CI（0.54，1.44），P = 0.609）、年龄（OR = 0.54，95%CI（0.21，1.36），P = 0.191）、包膜侵犯（OR = 2.98，95%CI（0.23，38.29），P = 0.403）或肿瘤多灶性（OR = 0.25，95%CI（0.003，19.28），P = 0.533）无关。
本研究表明，STAT3蛋白表达与甲状腺癌的易感性和临床病理特征显著相关。这也提示STAT3可能是甲状腺癌临床进展的一个潜在预测指标。
